Alleviation of pulmonary fibrosis by the dual PPAR agonist saroglitazar and breast milk mesenchymal stem cells via modulating TGFß/SMAD pathway

Pulmonary fibrosis (PF) is a complex disorder with high morbidity and mortality. Limited efficacies of the available drugs drive researchers to seek for new therapies. Saroglitazar (Saro), a full (PPAR α/γ) agonist, is devoid of known PPAR-mediated adverse effects. Breast milk mesenchymal stem cells...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Naunyn-Schmiedeberg's archives of pharmacology 2024-08, Vol.397 (8), p.5953-5974
Hauptverfasser:	Attia, Seba Hassan, Saadawy, Sara F., El-Mahroky, Samaa M., Nageeb, Mahitab M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Agonists Animals Autophagy Biomedical and Life Sciences Biomedicine Bleomycin Breast milk Breastfeeding & lactation Cell differentiation Female Fibrosis Immunosuppressive agents Inflammation Lung - drug effects Lung - metabolism Lung - pathology Lung diseases Male Mesenchymal Stem Cell Transplantation - methods Mesenchymal stem cells Mesenchymal Stem Cells - drug effects Mesenchymal Stem Cells - metabolism Morbidity Neurosciences Peroxisome proliferator-activated receptors Pharmacology/Toxicology Phenylpropionates - pharmacology PPAR alpha - agonists PPAR alpha - metabolism PPAR gamma - agonists PPAR gamma - metabolism Pulmonary fibrosis Pulmonary Fibrosis - drug therapy Pulmonary Fibrosis - metabolism Pulmonary Fibrosis - pathology Pyrroles Signal Transduction - drug effects Smad protein Stem cells Trachea Transforming Growth Factor beta - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!